Furthering Our Understanding of Delayed Neurotoxicity after CAR-T in Myeloma

Furthering Our Understanding of Delayed Neurotoxicity after CAR-T in Myeloma
Furthering Our Understanding of Delayed Neurotoxicity Post CAR-T in MM | Anupama Kumar, MD |#ASH24
Furthering Our Understanding of Delayed Neurotoxicity Post CAR-T in MM | Anupama Kumar, MD |#ASH24
Gamma Secretase Inhibition May Boost CAR-T Effectiveness in Some Myeloma | Andrew Portugese | #ASH24
Gamma Secretase Inhibition May Boost CAR-T Effectiveness in Some Myeloma
Gamma Secretase Inhibition May Boost CAR-T Effectiveness in Some Myeloma | Andrew Portugese | #ASH24
What is smoldering (asymptomatic) multiple myeloma?
Adding Isatuximab to Standard RVD May Improve Outcomes for Myeloma Patients | Elias Mai, MD | #ASH24
Adding Isatuximab to Standard RVD May Improve Outcomes for Myeloma Patients | Elias Mai, MD | #ASH24
Inobrodib in Combination with Pomalidomide and Dexamethasone in Myeloma | Emma Searle, MD | #ASH24
Inobrodib in Combination with Pomalidomide and Dexamethasone in Myeloma | Emma Searle, MD | #ASH24
Boosting Infection Protection in Myeloma Patients with IvIG Therapy | Betsy O’Donnell, MD | #ASH24
Boosting Infection Protection in Myeloma Patients with IvIG Therapy | Betsy O’Donnell, MD | #ASH24
Combination of Isatuximab, Carfilzomib, Lenalidomide, Dex in Myeloma | Elizabeth O'Donnell | #ASH24
Combination of Isatuximab, Carfilzomib, Lenalidomide, Dex in Myeloma | Elizabeth O'Donnell | #ASH24
Ethnicity's Impact on Myeloma Outcomes After Stem Cell Transplant | Frances Cervoni, MD | #ASH24
Ethnicity's Impact on Myeloma Outcomes After Stem Cell Transplant | Frances Cervoni, MD | #ASH24